The standard of care in AHF has remained largely unchanged since the 1970s, resulting in a highly genericized market. AHF patients continue to experience high rates of mortality and morbidity because no therapy to date has been able to improve hard clinical outcomes. In this report, we discuss how current therapies are differentiated based on their performance on key drug attributes and measure the impact of these attributes on cardiologists’ prescribing behavior. We also discuss the most important unmet needs in the treatment of AHF; according to physicians surveyed, the most important unmet need is reducing AHF patients’ mortality rate. Understanding the importance of these unmet needs helps identify the most attractive opportunities in AHF treatment. We then consider which emerging therapies, if any, can capitalize on these opportunities. Our conjoint analysis reveals the trade-offs in key attributes, such as rate of mortality, rehospitalization, and price, that surveyed physicians are willing to make when considering new treatment options for AHF.
- What are the treatment drivers and goals for AHF?
- Which attributes are the most influential, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for AHF?
- What are the prevailing areas of unmet need and opportunity in AHF?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European cardiologists for a hypothetical new AHF drug?
Markets covered: United States, France, Germany, United Kingdom.
Primary research: Survey of 60 U.S. and 30 European cardiologists fielded in January 2017.
Key companies:Bristol-Myers Squibb, Cardiorentis, Janssen, Novartis
Key drugs: inotropic sympathomimetics, loop diuretics, Natrecor, nitrate vasodilators, PDE3 inhibitors, serelaxin